In 2021, Nakano et al. [6] reported that a patient with ALK-positive NSCLC and controlled type 2 diabetes mellitus experienced profound hyperglycemia 92 days after starting lorlatinib. This evidence concerns the gene ALK and type 2 diabetes mellitus.